Consideration of Cardiovascular Morbidities in the Relationship between Ambient Air Pollution Exposure and Individual-Level Adverse COVID-19 Outcomes: A Systematic Review.

Consideration of Cardiovascular Morbidities in the Relationship between Ambient Air Pollution Exposure and Individual-Level Adverse COVID-19 Outcomes: A Systematic Review.

Publication date: Dec 01, 2025

Studies suggest ambient air pollution increases risk of individual-level adverse COVID-19 outcomes. Our review seeks to understand how air pollution influences adverse COVID-19 outcomes, by identifying how researchers accounted for cardiovascular morbidity, a predominant COVID-19 risk factor that is strongly linked to air pollution exposure. Our review primarily consisted of retrospective cohorts from the US and Europe, that examined both historical and short-term air pollution. Studies typically found that air pollution was associated with greater risk of individual-level adverse COVID-19 outcomes and adjusted for cardiovascular morbidities as confounders. Few hypothesized cardiovascular morbidity as a mediator or effect modifier in this relationship. Improved understanding of cardiovascular morbidity’s potential role as an effect modifier or mediator can help better explain the link between air pollution and COVID-19, in addition to identifying and assisting populations that may be at greater risk for adverse pandemic outcomes.

Open Access PDF

Concepts Keywords
Cardiovascular Air pollution
Covid Cardiovascular morbidity
Europe COVID-19
Pandemic Environmental exposure
Retrospective Infectious disease severity

Semantics

Type Source Name
drug DRUGBANK Medical air
disease MESH COVID-19
drug DRUGBANK Tropicamide
disease MESH CAM
disease MESH HHS
disease MESH PMC
drug DRUGBANK Ozone
drug DRUGBANK Activated charcoal
drug DRUGBANK Angiotensin II
pathway REACTOME Immune System
disease MESH acute respiratory distress syndrome
disease MESH obesity
disease MESH dyslipidemia
disease MESH hypertension
disease MESH cardiovascular diseases
disease MESH atrial fibrillation
disease MESH ischemic heart disease
disease MESH myocardial infarction
disease MESH pulmonary heart disease
disease MESH stroke
drug DRUGBANK Icosapent
disease MESH included
disease MESH infection
disease MESH cerebrovascular disease
disease MESH emergency
disease MESH heart failure
disease MESH overweight
disease MESH long COVID
disease MESH Allergy
disease MESH Infectious Diseases
disease MESH Dis
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Dapsone
disease MESH DDS
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Ephedra
disease MESH death
drug DRUGBANK Troleandomycin
disease MESH viral infections
disease MESH Cytokine Storm
drug DRUGBANK Guanosine
disease MESH weight gain
disease MESH PDR
disease MESH multiple sclerosis
disease MESH pneumonia
disease MESH syndrome
disease MESH rheumatic disease
drug DRUGBANK Oxygen
drug DRUGBANK Aspartame
pathway REACTOME Infectious disease

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *